MedPath

Mirodenafil

Generic Name
Mirodenafil
Drug Type
Small Molecule
Chemical Formula
C26H37N5O5S
CAS Number
862189-95-5
Unique Ingredient Identifier
504G362H0H
Background

Mirodenafil has been used in trials studying the treatment and supportive care of Kidney Diseases, Urologic Diseases, Renal Insufficiency, Erectile Dysfunction, and Male Erectile Dysfunction.

Clinical Trials
Related News

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Phase 3
Active, not recruiting
Conditions
Alzheimer Disease
Interventions
Drug: Placebo
First Posted Date
2022-09-08
Last Posted Date
2025-04-23
Lead Sponsor
AriBio Co., Ltd.
Target Recruit Count
1150
Registration Number
NCT05531526
Locations
🇺🇸

Kingfisher Cooperative, Spokane, Washington, United States

🇺🇸

Vaught Neurological Services, PLLC, Crab Orchard, West Virginia, United States

🇺🇸

Medical College of Wisconsin, Wauwatosa, Wisconsin, United States

and more 99 locations

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2018-08-10
Last Posted Date
2021-07-21
Lead Sponsor
AriBio Co., Ltd.
Target Recruit Count
210
Registration Number
NCT03625622
Locations
🇺🇸

Advanced Clinical Research, Meridian, Idaho, United States

🇺🇸

Meridien Research - Spring Hill, Spring Hill, Florida, United States

🇺🇸

IMIC, Inc, Palmetto Bay, Florida, United States

and more 17 locations

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg

Phase 1
Completed
Conditions
Drug Interaction Potentiation
Interventions
First Posted Date
2015-06-30
Last Posted Date
2015-06-30
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
36
Registration Number
NCT02485028

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg

Phase 1
Completed
Conditions
Drug Interaction Potentiation
Interventions
First Posted Date
2015-06-30
Last Posted Date
2015-06-30
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
36
Registration Number
NCT02485041

Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients

Phase 1
Completed
Conditions
Urologic Diseases
Kidney Diseases
Renal Insufficiency
Interventions
First Posted Date
2010-11-02
Last Posted Date
2015-01-15
Lead Sponsor
Asan Medical Center
Target Recruit Count
12
Registration Number
NCT01232010
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Placebo
First Posted Date
2008-06-26
Last Posted Date
2013-04-18
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
112
Registration Number
NCT00705861
Locations
🇰🇷

SK Chemicals Co., Ltd, Seoul, Korea, Republic of

Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Placebo
First Posted Date
2008-03-26
Last Posted Date
2013-04-18
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
109
Registration Number
NCT00644007
Locations
🇰🇷

SK Chemicals Co., Ltd, Seoul, Korea, Republic of

Phase I Study to Investigate the Alcohol Interaction of SK3530

Phase 1
Completed
Conditions
Erectile Dysfunction
First Posted Date
2007-06-21
Last Posted Date
2007-06-21
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
18
Registration Number
NCT00489450
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530

Phase 1
Completed
Conditions
Erectile Dysfunction
First Posted Date
2007-06-21
Last Posted Date
2007-06-21
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
16
Registration Number
NCT00489606
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Phase 1 Study of SK3530 to Investigate of the Effect of Food

Phase 1
Completed
Conditions
Erectile Dysfunction
First Posted Date
2007-03-06
Last Posted Date
2013-04-18
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
15
Registration Number
NCT00443625
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy